Literature DB >> 31611360

Successful Systemic and Topical Treatment of Mycobacterium abscessus Otomastoiditis.

Floor van Wijk1,2, Jérôme Waterval3,4, Koen van Aerde1, Stefanie S V Henriet1, F J Anton Meijer5, Lennaert C Borra6, Rob E Aarnoutse6, Jakko van Ingen7.   

Abstract

Mycobacterium abscessus is an extensively drug-resistant opportunistic pathogen that can cause chronic otomastoiditis. There are no evidence-based treatment regimens for this severe infection. We treated four children with M. abscessus otomastoiditis with a structured regimen of topical imipenem and tigecycline, intravenous imipenem and tigecycline, and oral clofazimine and azithromycin and adjunctive surgery. This structured approach led to cure, with 1 year of follow-up after treatment. Adverse events were frequent, mostly caused by tigecycline.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Mycobacteriumzzm321990; Mycobacterium abscessuszzm321990; clofazimine; experimental therapeutics; mastoiditis; otitis; otitis media; pediatric drug therapy; tigecycline

Year:  2019        PMID： 31611360      PMCID： PMC7187624          DOI： 10.1128/AAC.01203-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.

Authors:  David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop
Journal:  Am J Respir Crit Care Med       Date:  2007-02-15       Impact factor: 21.405

2.  Otomastoiditis caused by non-tuberculous mycobacteria: report of 16 cases, 3 with infection intracranially.

Authors:  L Lundman; H Edvardsson; K Ängeby
Journal:  J Laryngol Otol       Date:  2015-07       Impact factor: 1.469

3.  Tigecycline Is Highly Efficacious against Mycobacterium abscessus Pulmonary Disease.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 4.  Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.

Authors:  Moloko C Cholo; Maborwa T Mothiba; Bernard Fourie; Ronald Anderson
Journal:  J Antimicrob Chemother       Date:  2016-10-20       Impact factor: 5.790

5.  Failure of the Amikacin, Cefoxitin, and Clarithromycin Combination Regimen for Treating Pulmonary Mycobacterium abscessus Infection.

Authors:  Beatriz E Ferro; Shashikant Srivastava; Devyani Deshpande; Jotam G Pasipanodya; Dick van Soolingen; Johan W Mouton; Jakko van Ingen; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-09-23       Impact factor: 5.191

6.  Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions.

Authors:  F P Bigley; R J Forsyth; M W Henley
Journal:  Am J Hosp Pharm       Date:  1986-11

7.  Clofazimine Prevents the Regrowth of Mycobacterium abscessus and Mycobacterium avium Type Strains Exposed to Amikacin and Clarithromycin.

Authors:  Beatriz E Ferro; Joseph Meletiadis; Melanie Wattenberg; Arjan de Jong; Dick van Soolingen; Johan W Mouton; Jakko van Ingen
Journal:  Antimicrob Agents Chemother       Date:  2015-12-07       Impact factor: 5.191

8.  Clinical experience in 52 patients with tigecycline-containing regimens for salvage treatment of Mycobacterium abscessus and Mycobacterium chelonae infections.

Authors:  Richard J Wallace; Gary Dukart; Barbara A Brown-Elliott; David E Griffith; Ernesto G Scerpella; Bonnie Marshall
Journal:  J Antimicrob Chemother       Date:  2014-03-14       Impact factor: 5.790

9.  A novel formulation of tigecycline has enhanced stability and sustained antibacterial and antileukemic activity.

Authors:  Yulia Jitkova; Marcela Gronda; Rose Hurren; Xiaoming Wang; Carolyn A Goard; Bozhena Jhas; Aaron D Schimmer
Journal:  PLoS One       Date:  2014-05-28       Impact factor: 3.240
  9 in total
  3 in total

1.  No Amikacin, No Problem: a Successful Treatment Approach for Pediatric Otomastoiditis Due to Amikacin-Resistant Mycobacterium abscessus.

Authors:  William J Richter; Keira A Cohen
Journal:  Antimicrob Agents Chemother       Date:  2019-12-20       Impact factor: 5.191

2.  Quality of life in children receiving treatment for Mycobacterium abscessus otomastoiditis.

Authors:  Theresa Y S Leow; Stijn Bekkers; Arno M Janssen; Sjoert A H Pegge; Henricus P M Kunst; Jerome J Waterval; Thijs T G Jansen; Stefanie S V Henriet; Koen J van Aerde; Jakko van Ingen; Myrthe K S Hol
Journal:  Clin Otolaryngol       Date:  2022-03-30       Impact factor: 2.729

3.  Inhaled tigecycline is effective against Mycobacterium abscessus in vitro and in vivo.

Authors:  Camron Pearce; Mike M Ruth; Lian J Pennings; Heiman F L Wertheim; Amanda Walz; Wouter Hoefsloot; Carolien Ruesen; Juan Muñoz Gutiérrez; Mercedes Gonzalez-Juarrero; Jakko van Ingen
Journal:  J Antimicrob Chemother       Date:  2020-07-01       Impact factor: 5.790
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.